Understanding how engineered T cells work differently in cancer treatment
Official title: Dissecting intrinsic variability in engineered T Cell immunotherapies
Funded at Stanford University · NIH-10985388 · Data updated 2026-11-12
This study is looking at how different types of engineered T cells, called CAR T cells, work for cancer patients, with the goal of finding the best ways to customize these treatments so they can help each person more effectively.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $330,942 |
| NIH project number | 1K08CA286740-01A1 |
| Project ID | NIH-10985388 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients, particularly those with liquid tumors, who are considering or currently undergoing CAR T cell therapy.
✕Less likely to help
Patients with solid tumors who are not eligible for CAR T cell therapy may not benefit from this research.
What this research studies
This research investigates the variability in responses of engineered T cells, specifically Chimeric Antigen Receptor (CAR) T cells, in cancer patients. By developing new methods to test these T cells across a wide range of patients, the research aims to identify which specific modifications to the T cells can lead to better outcomes for individual patients. The approach includes screening various CAR T cell constructs and analyzing patient-specific responses to optimize treatment strategies. Ultimately, the goal is to create personalized immunotherapies that improve the effectiveness of cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments for patients using engineered T cells.
How similar studies have gone: Other research has shown promise in personalizing cancer immunotherapies, but this specific approach to dissecting T cell variability is relatively novel.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Roth, Theodore Lee — Stanford University
- Study coordinator: Roth, Theodore Lee
Related research
Other NIH-funded projects on the same topics.
-
Multimodal AI to predict CAR-T patient response and guide safer, smarter cell design
A Stanford team is building AI tools that use patient and CAR-T cell data to predict how well a CAR-T therapy will work and what design changes might boost effectiveness and safety for people with cancer.
-
Community-driven model to reduce overdose deaths through smarter resource use
A Stanford-led project uses a data-driven model to help counties pick the best ways to prevent opioid and stimulant overdoses and save lives.
-
Center for Dissemination and Implementation at Stanford: Research Core
A Stanford-based program is advancing how evidence-based addiction treatments are implemented across settings to help people with substance use disorders receive better care.
-
Center for Dissemination and Implementation At Stanford (C-DIAS)
A center-based program at Stanford aims to speed people who need addiction treatments to get evidence-based care.
-
Mitochondrial structure and neuron health in Alzheimer's and ALS
This grant studies how mitochondrial cristae structure in neurons is controlled and how its disruption may contribute to diseases like Alzheimer's and ALS.
-
Pediatric EMS seizures: simpler age-based midazolam dosing
A nationwide trial at EMS agencies tests whether using fixed, age-based dosing of midazolam for seizures in children improves treatment speed and safety.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.